
Supplemental Table 1. Cohort Characteristics

				Days from	Days from	Days from			Positive	Days from
			Completed	End of N/R	End of N/R	End of N/R	Enrollment	Days from	Culture	Diagnosis
			COVID-19	Therapy to	Therapy to	Therapy to	Viral Load	Diagnosis	After	to Negative
		Age	Vaccinations	Symptom	Antigen	Study	(Log10	to Negative	Relapse	Viral
ID	Gender	Range	at Enrollment	Relapse	Positivity	Enrollment	copies/mL)	PCR	(Y/N)	Culture
1	F	31-35	4	4	5	9	4.7	20	N	N/A
2	M	51-55	3	5	5	8	6.8	23	Y	16
3	F	46-50	3	7	4	7	4.2	23	N	N/A
4	F	51-55	5	4	4	7	6.1	18	N	N/A
5	F	46-50	4	2	5	6	7.3	16	Y	14
6	F	61-65	3	3	6	8	4.9	19	N	N/A
7	F	36-40	3	6	8	10	7.1	19	Y	19

N/R: nirmatrelvir-ritonavir

N/A: not applicable



ORF1a: NSP5 Amino Acid Position

Supplemental Figure 1. Amino acid sequence of NSP5 (main viral protease, or Mpro) for individuals with recurring infection following nirmatrelvir-ritonavir treatment, compared to reference WT genome (GenBank YP_009725301.1). Ref-BA.2 (USA/MA-MGB-06410/2022) and Ref-BA.2.12.1 (USA/MA-MGB-05617/2022) genomes were collected via MGH surveillance sequencing and used as lineage-specific references. No mutations were found in drug-resistance conferring regions of the NSP5 gene of the six sequenced specimens.